Nsclc Trials in Shanghai, China
Conditions / Nsclc / Shanghai, China
Nsclc is a medical condition with active clinical research programs worldwide.
51 total trials for this combination
Showing top 10 of 51 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05687266 | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations | ACTIVE_NOT_RECRUITING | — |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | UNKNOWN | PHASE1/PHASE2 |
| NCT05383482 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | COMPLETED | PHASE1/PHASE2 |
| NCT04746924 | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03861156 | D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer | COMPLETED | PHASE2 |
| NCT05687266 | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations | ACTIVE_NOT_RECRUITING | — |
| NCT06107686 | A Study of YL202 in Selected Patients With Advanced Solid Tumors | RECRUITING | PHASE2 |
| NCT06422143 | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | RECRUITING | — |
| NCT06422143 | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | RECRUITING | — |
| NCT05687266 | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations | ACTIVE_NOT_RECRUITING | — |